ArticleVirology2019
Lack of nsP2-specific nuclear functions attenuates chikungunya virus replication both in vitro and in vivo.
Article in Virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Intrahost population dynamics of chikungunya virus in humans and naturally infectedVirus evolution · 2026Article
- Article
- Viral interference of nucleocytoplasmic transport.The Journal of biological chemistry · 2025Review
- [Mother-to-Child Transmission of Chikungunya Virus and Its Impact on the Neonatal Nervous System].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Review
- Getah virus nonstructural protein 2 suppresses interferon-beta production by interrupting interferon regulatory factor 3 activation.Veterinary research · 2025Article
- A chimeric viral platform for directed evolution in mammalian cells.Nature communications · 2025Article
- Alphavirus nsP2: A Multifunctional Regulator of Viral Replication and Promising Target for Anti-Alphavirus Therapies.Reviews in medical virology · 2025Review
- Article
- Translational Control of Alphavirus-Host Interactions: Implications in Viral Evolution, Tropism and Antiviral Response.Viruses · 2024Review
- Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development.Pathogens (Basel, Switzerland) · 2023Review
- Novel Mutations in the Non-Structure Protein 2 of SARS-CoV-2.Mediterranean journal of hematology and infectious diseases · 2023Article
- Developing brain under renewed attack: viral infection during pregnancy.Frontiers in neuroscience · 2023Review
- Influence of host genetic polymorphisms involved in immune response and their role in the development of Chikungunya disease: a review.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Review
- Characterization and Involvement of Exosomes Originating from Chikungunya Virus-Infected Epithelial Cells in the Transmission of Infectious Viral Elements.International journal of molecular sciences · 2022Article
- The lncRNA ALPHA specifically targets chikungunya virus to control infection.Molecular cell · 2022Article
- Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling.Journal of virology · 2022Article
- Optimized production and immunogenicity of an insect virus-based chikungunya virus candidate vaccine in cell culture and animal models.Emerging microbes & infections · 2021Article
- NAP1L1 and NAP1L4 Binding to Hypervariable Domain of Chikungunya Virus nsP3 Protein Is Bivalent and Requires Phosphorylation.Journal of virology · 2021Article
- Facile method for delivering chikungunya viral replicons into mosquitoes and mammalian cells.Scientific reports · 2021Article
- Pyrimidone inhibitors targeting Chikungunya Virus nsP3 macrodomain by fragment-based drug design.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Chikungunya virus (CHIKV) is an important arthritogenic human pathogen that is already circulating in both hemispheres. In the present study, we substituted VLoop, located on the surface of nsP2, by other amino acid sequences. These modifications had deleterious effects on viral nuclear functions and made CHIKV incapable of interfering with the induction of type I interferon and the antiviral response in both mouse and human cells. Importantly, the identified mutations have no significant effects on the synthesis of virus-specific RNAs and viral structural proteins. The designed mutants induced a few orders of magnitude lower viremia but remained highly immunogenic in mice. Thus, the proposed modifications of nsP2 can additionally improve the safety of the attenuated strain CHIKV 181/25. Furthermore, defined mutations in the macro domain of another nonstructural protein, nsP3, additionally reduce cytopathogenicity of nsP2 mutants in human cells, and can be potentially applied for CHIKV attenuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.